Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down before the market opened on Wednesday . The stock had previously closed at $21.16, but opened at $20.01. Ascentage Pharma Group International shares last traded at $21.6050, with a volume of 276 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $46.67.

Ascentage Pharma Group International Price Performance

The firm’s 50 day simple moving average is $23.95 and its two-hundred day simple moving average is $26.94. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million for the quarter. Equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors have recently modified their holdings of the business. UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $383,000. XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the period. Finally, ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.